S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:REGN

Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

$628.71
+4.81 (+0.77%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$622.31
$632.57
50-Day Range
$548.35
$641.49
52-Week Range
$538.01
$747.42
Volume
349,822 shs
Average Volume
690,586 shs
Market Capitalization
$68.24 billion
P/E Ratio
12.55
Dividend Yield
N/A
Price Target
$698.35

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
11.1% Upside
$698.35 Price Target
Short Interest
Bearish
2.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
-0.06mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$31.66 M Sold Last Quarter
Proj. Earnings Growth
6.80%
From $35.90 to $38.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

213th out of 1,117 stocks

Pharmaceutical Preparations Industry

98th out of 550 stocks

REGN stock logo

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $623.90 on Friday. Regeneron Pharmaceuticals has a 52 week low of $538.01 and a 52 week high of $747.42. The company has a quick ratio of 4.39, a current ratio of 5.12 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $67.72 billion, a PE ratio of 12.45, a price-to-earnings-growth ratio of 2.17 and a beta of 0.29. The stock's 50-day moving average price is $596.03 and its 200-day moving average price is $636.26.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Rating) last posted its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 EPS for the quarter, missing analysts' consensus estimates of $9.94 by ($0.17). Regeneron Pharmaceuticals had a net margin of 39.97% and a return on equity of 36.17%. The business had revenue of $2.86 billion for the quarter, compared to analyst estimates of $2.80 billion. During the same quarter last year, the business earned $27.97 earnings per share. Regeneron Pharmaceuticals's revenue was down 44.4% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals will post 35.9 EPS for the current fiscal year.

Analysts Set New Price Targets

REGN has been the topic of several recent research reports. StockNews.com cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Tuesday, July 26th. Jefferies Financial Group cut Regeneron Pharmaceuticals to a "sell" rating and set a $536.00 target price on the stock. in a research report on Friday, June 17th. Cowen increased their target price on Regeneron Pharmaceuticals from $635.00 to $645.00 in a research report on Wednesday, July 20th. Cowen increased their target price on Regeneron Pharmaceuticals to $655.00 in a research report on Tuesday. Finally, Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, July 12th. They set a "neutral" rating and a $625.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $698.35.

Insider Buying and Selling

In related news, EVP Neil Stahl sold 23,782 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $612.61, for a total value of $14,569,091.02. Following the sale, the executive vice president now directly owns 52,795 shares in the company, valued at approximately $32,342,744.95. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, EVP Neil Stahl sold 23,782 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $612.61, for a total value of $14,569,091.02. Following the sale, the executive vice president now directly owns 52,795 shares in the company, valued at approximately $32,342,744.95. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Marion Mccourt sold 1,100 shares of the business's stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $587.76, for a total value of $646,536.00. Following the transaction, the executive vice president now owns 19,644 shares in the company, valued at $11,545,957.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 51,435 shares of company stock worth $31,663,304. Insiders own 8.99% of the company's stock.

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Stock News Headlines

How Much Longer Will It Be Under $1?
The SEC and a group of high-powered lawyers have been hashing out a federally-regulated cryptocurrency. Once ready, this crypto will become the 1st endorsed for use in the US. I expect once the regulations are in place, this crypto's value will skyrocket. Get into this crypto for under a dollar now. pixel
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Regeneron's 'Regeneration' May Not Last Long
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings
8/03/2022
Today
8/12/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
10,368
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$698.35
High Stock Price Forecast
$844.00
Low Stock Price Forecast
$536.00
Forecasted Upside/Downside
+11.1%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
19 Analysts

Profitability

Net Income
$8.08 billion
Pretax Margin
44.59%

Debt

Sales & Book Value

Annual Sales
$16.07 billion
Cash Flow
$79.28 per share
Book Value
$189.78 per share

Miscellaneous

Free Float
98,781,000
Market Cap
$68.24 billion
Optionable
Optionable
Beta
0.29

Social Links















REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 2 sell ratings, 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" REGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in REGN, but not buy additional shares or sell existing shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price forecast for 2022?

19 Wall Street research analysts have issued 12-month price targets for Regeneron Pharmaceuticals' shares. Their REGN share price forecasts range from $536.00 to $844.00. On average, they predict the company's stock price to reach $698.35 in the next year. This suggests a possible upside of 10.7% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2022?

Regeneron Pharmaceuticals' stock was trading at $631.52 at the beginning of 2022. Since then, REGN stock has decreased by 0.2% and is now trading at $630.57.
View the best growth stocks for 2022 here
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our REGN earnings forecast
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings data on Wednesday, August, 3rd. The biopharmaceutical company reported $9.77 EPS for the quarter, missing the consensus estimate of $9.94 by $0.17. The biopharmaceutical company earned $2.86 billion during the quarter, compared to analysts' expectations of $2.80 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 36.17% and a net margin of 39.97%. The business's revenue for the quarter was down 44.4% compared to the same quarter last year. During the same period in the previous year, the company earned $27.97 earnings per share.
Read the conference call transcript
.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (9.34%), Loomis Sayles & Co. L P (1.63%), California Public Employees Retirement System (0.71%), Franklin Resources Inc. (0.48%), Swiss National Bank (0.43%) and Sumitomo Mitsui Trust Holdings Inc. (0.37%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry, Robert E Landry and Sanofi.
View institutional ownership trends
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $630.57.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $68.74 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $50.10 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

The company employs 10,368 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More

When was Regeneron Pharmaceuticals founded?

Regeneron Pharmaceuticals was founded in 1988.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.